Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Myrbetriq is the first and only beta-3 adrenergic agonist indicated for the treatment of overactive bladder NORTHBROOK, Ill., June 28, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a...
Read more about FDA Approves Overactive Bladder Treatment Myrbetriq™ (mirabegron) from Astellas
Event Kicks Off Astellas' Annual Changing Tomorrow Day Volunteer Initiative KISSIMMEE, Fla., June 13, 2012 /PRNewswire/ -- Give Kids The World Village (GKTW) will host its largest single...
Japanese Pharmaceutical Company Expands in Glenview GLENVIEW, Ill. – June 4, 2012. Governor Pat Quinn today joined Astellas executives and more than 1,000 employees to open the company’s new...
Dose-Escalation Completed and Preliminary Antitumor Activity Observed Santa Monica, CA and Bothell, WA – June 4, 2012 – Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and...
On May 21, 2012, the American Urological Association (AUA) issued the first guidelines specific to the diagnosis and treatment of overactive bladder (OAB) in the U.S. Astellas supports these new...
Read more about Astellas Statement Regarding New Overactive Bladder Guidelines
Follow U.S. news
